Dilation and Curettage (D&C) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Dilation and curettage (D&C) is a gynaecological surgical procedure involving two steps: cervical dilation — gradual mechanical or pharmacological widening of the cervical os (the opening of the uterus) — followed by curettage — scraping or suction removal of the uterine lining (endometrium) and uterine cavity contents using a curette or suction cannula. It is one of the most commonly performed gynaecological procedures globally and serves both diagnostic purposes (endometrial sampling for pathological analysis) and therapeutic purposes (removal of retained products of conception, treatment of abnormal uterine bleeding, and management of endometrial polyps).

The procedure is typically performed under general or spinal anaesthesia in an operating theatre. The patient is placed in lithotomy position (lying on the back with legs in stirrups). The cervix is exposed with a vaginal speculum, cleaned with antiseptic, and grasped with a tenaculum. The uterus is sounded (measured for depth) and the cervix is sequentially dilated using graduated metal dilators (Hegar dilators) until the appropriate size is achieved (typically 7–10 mm for most indications). The endometrial cavity is then curetted with a sharp metal curette and/or aspirated with a suction curette, and the specimen is sent for histopathology.

Modern practice increasingly uses hysteroscopy — a camera inserted into the uterine cavity — alongside D&C, allowing direct visualisation of the endometrium before and after curettage, targeted biopsy of suspicious areas, and intrauterine therapeutic procedures such as polyp removal and endometrial ablation under direct vision.

D&C serves multiple diagnostic and therapeutic indications in gynaecology. As a diagnostic procedure, it is performed to evaluate abnormal uterine bleeding (particularly post-menopausal bleeding, which must be investigated to exclude endometrial carcinoma), to obtain endometrial tissue for histological assessment when office endometrial biopsy is inconclusive or cannot be performed, and to evaluate thickened endometrium identified on ultrasound (endometrial thickness above 4–5 mm post-menopause is an indication for sampling).

Therapeutic indications include: incomplete miscarriage (retained products of conception following spontaneous miscarriage or fetal demise — D&C removes retained placental and fetal tissue to prevent infection and haemorrhage); missed miscarriage (intrauterine fetal demise with retained products); management of gestational trophoblastic disease (hydatidiform mole requires suction curettage with careful follow-up of beta-hCG); treatment of endometrial polyps (though hysteroscopic polypectomy is now preferred for targeted removal); and as part of hysteroscopic procedures for intrauterine pathology. D&C for elective termination of pregnancy (surgical abortion, first trimester) uses suction curettage (MVA — manual vacuum aspiration, or EVA — electric vacuum aspiration).

Candidates for diagnostic D&C include post-menopausal women with any vaginal bleeding, premenopausal women with abnormal uterine bleeding refractory to medical management or with risk factors for endometrial pathology (obesity, PCOS, tamoxifen use, hereditary non-polyposis colorectal cancer syndrome), and women with abnormal imaging findings (thickened endometrium on ultrasound). Therapeutic D&C is indicated for incomplete or missed miscarriage with retained products of conception (RPOC) confirmed on ultrasound.

Contraindications include active pelvic inflammatory disease (PID) — the procedure should be deferred until infection is treated, as curettage risks spreading infection. Uterine perforation risk is higher in post-menopausal women (thin, stenosed cervix) and in women with previous uterine surgery (uterine fibroids, previous caesarean section with uterine adhesions). Pregnancy — where the intention is not termination or management of miscarriage — is an absolute contraindication. Coagulopathy requires correction before the procedure to reduce haemorrhage risk.

Sharp curettage — using a metal curette to systematically scrape the four walls and fundus of the uterine cavity — is the traditional D&C technique. Suction curettage (vacuum aspiration) uses a suction cannula connected to an electrical or manual vacuum source (12.5 mmHg negative pressure) to aspirate endometrial contents — this is faster, causes less cervical trauma, and is the preferred method for evacuation of retained products of conception and surgical abortion.

Hysteroscopy-guided D&C combines camera-based visualisation with targeted curettage or biopsy, ensuring complete sampling of the entire endometrial cavity and enabling targeted treatment of focal lesions (polyps, submucous fibroids) that blind D&C might miss. This is now the preferred approach in most elective diagnostic D&C procedures. Pharmacological cervical preparation — using misoprostol (prostaglandin E1 analogue) vaginally or sublingually 2–4 hours before the procedure — softens and dilates the cervix, reducing the force required for mechanical dilation and the risk of cervical injury. This is particularly important in post-menopausal women, nulliparous women, and those with a previous loop excision or cone biopsy. Shared decision-making between the patient and specialist ensures the chosen modality aligns with individual anatomy, comorbidities, risk tolerance, and personal goals. A formal consultation with a board-certified specialist, review of pre-treatment imaging or investigation results, and multidisciplinary team input for complex cases are standard practice before finalising the treatment plan.

D&C is highly effective for its diagnostic and therapeutic indications. Diagnostic D&C provides endometrial tissue adequate for histopathological assessment in over 90% of cases, enabling detection of endometrial carcinoma, atypical hyperplasia, complex hyperplasia, and benign polyps. For incomplete miscarriage, suction curettage achieves complete uterine evacuation in over 95% of cases, with significant relief of haemorrhage and risk of sepsis.

Recovery is rapid — most patients resume normal activities within 1–3 days. The short procedure duration (15–30 minutes) and day-case nature mean minimal disruption to daily life. Diagnostic D&C has high sensitivity for endometrial carcinoma and atypical hyperplasia when combined with hysteroscopy — missed cancer rates are below 1% when performed by an experienced gynaecologist. Successful treatment significantly improves health-related quality of life metrics and may reduce long-term healthcare utilisation by preventing disease progression and complications. Regular follow-up after treatment enables early identification of recurrence or secondary issues, preserving long-term outcomes.

Uterine perforation — penetration of the uterine wall by the sound, dilator, or curette — occurs in approximately 0.3–1.2% of D&C procedures. Most perforations are minor and managed conservatively with observation; large perforations or those involving bowel require laparoscopy or laparotomy to assess visceral injury. Cervical laceration from tenaculum or dilators is uncommon.

Haemorrhage — significant bleeding during or after D&C — is uncommon with diagnostic D&C but more relevant for therapeutic procedures (RPOC evacuation, molar pregnancy) where the placental bed is highly vascular. Asherman's syndrome — intrauterine adhesion formation (endometrial synechiae) — is a recognised complication of aggressive or repeated curettage, leading to reduced menstrual flow, secondary infertility, and recurrent miscarriage. Risk is highest in D&C performed in the immediate post-partum or post-abortion period when the endometrium is most vulnerable. Infection/endometritis occurs in 1–3% of cases and is managed with antibiotics. Most centres use a single dose of prophylactic antibiotics pre-procedure.

Recovery from D&C is generally very quick. Light vaginal spotting or bleeding is expected for 1–2 weeks post-procedure and is normal. Moderate to heavy bleeding, fever (above 38°C), offensive vaginal discharge, or severe pelvic pain should prompt urgent clinical review to exclude retained products, infection, or haematometra (blood collection in the uterine cavity due to cervical stenosis).

Activity restrictions are minimal: most patients can return to work within 1–3 days, and sexual intercourse should be avoided for 2–4 weeks to reduce infection risk. Histopathology results are available within 5–10 working days. Results discussion at a follow-up clinic appointment determines further management — surveillance hysteroscopy for pre-malignant endometrial changes, oncology referral for carcinoma, hormonal treatment for hyperplasia, or reassurance for benign findings. Beta-hCG serial measurement is essential post-suction curettage for hydatidiform mole.

In the United States, D&C as a day surgery procedure costs $3,000–$8,000 including surgeon, anaesthesia, and facility fees. Hysteroscopy combined with D&C costs $4,000–$10,000. In the UK (private), D&C costs £1,500–£3,000; hysteroscopy with D&C £2,000–£4,500.

For medical tourists, D&C at gynaecology centres in India, Thailand, and Turkey costs $300–$800 for a standard diagnostic D&C; $500–$1,500 for hysteroscopy with D&C. Leading gynaecology hospitals in these destinations offer high-definition hysteroscopes, experienced gynaecologists, and day-case pathways at 70–90% savings versus Western private rates. Patients are advised to obtain itemised cost estimates from multiple providers and verify insurance coverage or national health system entitlements before proceeding. Medical tourism at accredited hospitals in India, Thailand, Turkey, or Mexico can reduce total procedure costs by 50–80% compared to US or UK pricing, with internationally trained specialists and comparable clinical outcomes for elective procedures.

Office endometrial biopsy (Pipelle sampler) — a narrow plastic disposable aspiration device inserted through the cervix without anaesthesia in a clinic setting — is the first-line investigation for abnormal uterine bleeding and post-menopausal bleeding in most guidelines. It provides a tissue sample adequate for histology in 90% of cases, at lower cost and without anaesthesia. Its main limitation is that it samples only a small portion of the endometrial cavity and may miss focal pathology (polyps, submucous fibroids).

For management of incomplete miscarriage, expectant management (waiting for natural expulsion of retained products) is appropriate for haemodynamically stable patients willing to wait 1–2 weeks (complete expulsion in 50–85%), and medical management with misoprostol achieves complete expulsion in 70–85% within 2 weeks. Surgical management (D&C) is more reliable but carries procedural risks. Patient preference and clinical urgency guide the choice between these three management strategies. For recurrent pregnancy loss, investigations before repeat D&C should include karyotyping of products of conception.